Skip to content
Back to search

Poland – Pharmaceutical products – „Dostawa leków dla całego szpitala Megrez Sp. z o.o.” Nr postępowania: 24/26/ZP/PN

Megrez Sp. z o.o.PolandPublished on Aug 20, 2026
31 days left

Description

The subject of the contract is the Supply of medicines for the entire Megrez Sp. z o.o. Hospital. 2. The subject of the contract is subject to the provisions of the Act of 12 May 2011 on the reimbursement of medicines, special purpose foodstuffs and medical devices (Journal of Laws of 2011, No. 122, item 696, as amended). 3. In the case of medicines, special purpose foodstuffs and medical devices covered by the reimbursement, the prices offered and applied by the Contractor may not exceed the maximum prices specified in accordance with Article 9(1) of the Act of 12 May 2011 on the reimbursement of medicines, special purpose foodstuffs and medical devices. 4. A detailed description of the subject of the contract is given in the assortment-price form - Annex No. 2 to the SWZ. 5. The Contractor is obliged to implement the contract on the principles and conditions of the provisions of the contract, which are Annex No. 4 to the SWZ. 6. Common Procurement Vocabulary (CPV): 33600000-6 – pharmaceutical products The Purchaser allows for the possibility of submitting partial offers. The contract consists of 15 lots (parts). The Contractor is entitled to submit an offer covering at least 1 lot (part). The lots must be priced in full. Offers not containing the full scope of the subject of the contract specified in the lot will be rejected. 7. In the assortment-price form, in the sections "Manufacturer and catalogue number, product name", only one name of the offered product (unless the subject of the contract requires more) and the name of the manufacturer of that product, which will allow for the unambiguous identification of the product on the market, should be given. 8. Each time a standard is indicated in this SWZ or in the annexes to the SWZ, it should be assumed that the formulation "or equivalent" has been used in relation to it. The Purchaser envisages the application of the option right: Within Task 4 up to 25% of the value of the basic contract. Within Task 7 up to 25% of the value of the basic contract. Within Task 10 up to 25% of the value of the basic contract. Within Task 11 up to 25% of the value of the basic contract. The Purchaser reserves the right to exercise the option right (in whole or in part) in the event that during the contract period the basic scope is exhausted and additionally the purchase of additional quantities of the product would be in the interest of the Purchaser and result from its current needs. In order to activate the option right, the Purchaser will submit to the Contractor a written statement of intent regarding the exercise of the option right within a specified scope. The statement will confirm the financial resources for the implementation of the contract and will be an annex to the contract. The option right is a unilateral right of the Purchaser, which it may, but is not obliged to, exercise within the framework of the implementation of the subject of the contract. In the event that the Purchaser does not exercise the option right, the Contractor will not be entitled to any claims in this regard. If the Purchaser exercises the option right, the Contractor's contractual obligation is to perform the service within the scope covered by the exercised option right on the same terms as the basic contract. The Purchaser has the right to exercise the option right multiple times after implementing the basic scope of the contract – but until the maximum scope of the option right is exhausted. The activation of the option will not require a change to the contract.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders